EFFICACY AND SAFETY OF ADALIMUMAB IN ANKYLOSING SPONDYLITIS: DATA FROM REAL LIFE
Romanian Journal of Rheumatology · 2015
DOI: 10.37897/rjr.2015.1.7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Romanian Journal of Rheumatology, 2015. Verfasst von Claudiu Popescu und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Rationale
Data from controlled trials showed that adalimumab, a humanized anti-TNF monoclonal antibody, is effective and safe in the treatment of ankylosing spondylitis (AS).
Objectives
The present study aimed to observe the effi cacy and safety of adalimumab in AS in a real life clinical setting.
Methods
The study observed cross-sectionaly and retrospectively the efficacy and safety of adalimumab in all the patients admitted to the Rheumatology Department of “Sfânta Maria” Clinical Hospital between January 2008 and June 2013 who were classified as having AS according to the modified New York criteria. The diagnosis and follow-up of uveitic cases were done in the Ophthalmology Department of the Emergency University Hospital.
Results
Within the study time-frame, 79 AS patients met the inclusion criteria: 71 (89.9%) had adalimumab for at least 24 months; 8 (10.1%) switched from adalimumab to another biological, as follows: 3 (3.8%) because of serious adverse events, 3 (3.8%) were primary non-responders and 2 (2.5%) were secondary non-responders. The clinical response was fast: after 3 months of treatment, 59 (83.1%) patients had BASDAI < 4 and 55 (77.5%) patients had BASFI < 4. Regarding safety, the serious adverse effects recorded were: infectious arthritis, pulmonary tuberculosis, pulmonary sarcoidosis. There were no cases of cancer or demyelinating disease during the study frame.
Conclusions
Therapy with adalimumab in AS produces a prompt and lasting effect. The efficacy (remission) and safety (adverse events) of adalimumab can be monitored in the real-life clinical setting using BASDAI, BASFI, and routine clinical evaluations. Clinicians may need to expect a slightly higher rate of serious adverse events and rate of treatment discontinuation than those reported by controlled trials.
Zitieren
APA
Popescu, C., Coroama, C., Mitulescu, C., Predeteanu, D., & Ionescu, R. (2015). EFFICACY AND SAFETY OF ADALIMUMAB IN ANKYLOSING SPONDYLITIS: DATA FROM REAL LIFE. Romanian Journal of Rheumatology. https://doi.org/10.37897/rjr.2015.1.7
Vancouver
Popescu C, Coroama C, Mitulescu C, Predeteanu D, Ionescu R. EFFICACY AND SAFETY OF ADALIMUMAB IN ANKYLOSING SPONDYLITIS: DATA FROM REAL LIFE. Romanian Journal of Rheumatology. 2015. doi:10.37897/rjr.2015.1.7
BibTeX
@article{Popescu2015,
author = {Popescu, Claudiu and Coroama, Cristina and Mitulescu, Costin and Predeteanu, Denisa and Ionescu, Ruxandra},
title = {EFFICACY AND SAFETY OF ADALIMUMAB IN ANKYLOSING SPONDYLITIS: DATA FROM REAL LIFE},
journal = {Romanian Journal of Rheumatology},
year = {2015},
doi = {10.37897/rjr.2015.1.7}
}
EUVIMED